The pharmacokinetic and pharmacodynamic properties of vancomycin
- PMID: 16323118
- DOI: 10.1086/491712
The pharmacokinetic and pharmacodynamic properties of vancomycin
Abstract
Vancomycin is one of only a few antibiotics available to treat patients infected with methicillin-resistant Staphylococcus aureus and methicillin-resistant, coagulase-negative Staphylococcus species. Therefore, understanding the clinical implications of the pharmacokinetic and pharmacodynamic properties of vancomycin is a necessity for clinicians. Vancomycin is a concentration-independent antibiotic (also referred to as a "time-dependent" antibiotic), and there are factors that affect its clinical activity, including variable tissue distribution, inoculum size, and emerging resistance. This article reviews the pharmacokinetic and pharmacodynamic data related to vancomycin and discusses such clinical issues as toxicities and serum concentration monitoring.
Similar articles
-
Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.Clin Microbiol Infect. 2008 Feb;14(2):116-23. doi: 10.1111/j.1469-0691.2007.01885.x. Epub 2007 Dec 10. Clin Microbiol Infect. 2008. PMID: 18076672
-
Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.J Antimicrob Chemother. 2009 Jan;63(1):155-60. doi: 10.1093/jac/dkn439. Epub 2008 Nov 4. J Antimicrob Chemother. 2009. PMID: 18984644
-
Limitations of vancomycin in the management of resistant staphylococcal infections.Clin Infect Dis. 2007 Sep 15;45 Suppl 3:S191-5. doi: 10.1086/519470. Clin Infect Dis. 2007. PMID: 17712746 Review.
-
In vitro inhibition of coagulase-negative staphylococci by vancomycin/aminoglycoside-loaded cement spacers.Infection. 2006 Apr;34(2):81-6. doi: 10.1007/s15010-006-5039-2. Infection. 2006. PMID: 16703297
-
Optimizing therapy for MRSA pneumonia.Semin Respir Crit Care Med. 2007 Dec;28(6):615-23. doi: 10.1055/s-2007-996408. Semin Respir Crit Care Med. 2007. PMID: 18095225 Review.
Cited by
-
Limited-sampling strategies for anti-infective agents: systematic review.Can J Hosp Pharm. 2009 Sep;62(5):392-401. doi: 10.4212/cjhp.v62i5.827. Can J Hosp Pharm. 2009. PMID: 22478922 Free PMC article.
-
Influence of age on frequency of vancomycin dosing.Can J Hosp Pharm. 2010 Jan;63(1):13-9. doi: 10.4212/cjhp.v63i1.863. Can J Hosp Pharm. 2010. PMID: 22478948 Free PMC article.
-
Vancomycin Dosage and Its Association with Clinical Outcomes in Pediatric Patients with Gram-Positive Bacterial Infections.Risk Manag Healthc Policy. 2020 Jun 29;13:685-695. doi: 10.2147/RMHP.S244836. eCollection 2020. Risk Manag Healthc Policy. 2020. PMID: 32636687 Free PMC article.
-
Effect of Vancomycin Loading Doses on the Attainment of Target Trough Concentrations in Hospitalized Children.J Pediatr Pharmacol Ther. 2020;25(5):423-430. doi: 10.5863/1551-6776-25.5.423. J Pediatr Pharmacol Ther. 2020. PMID: 32641912 Free PMC article.
-
Augmented Renal Clearance in a Case of Sepsis Leading to Vancomycin Failure Despite Increasing Dose As per the Estimated Glomerular Filtration Rate.Cureus. 2021 Mar 30;13(3):e14183. doi: 10.7759/cureus.14183. Cureus. 2021. PMID: 33936894 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical